Amgen (AMGN) Successfully Completes Acquisition Of Five Prime Therapeutics (FPRX) Apr 16, 2021 08:29AM
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics Apr 16, 2021 08:25AM
Amgen (AMGN) To Acquire Five Prime Therapeutics (FPRX) For $1.9 Billion in Cash, $38/share Mar 4, 2021 08:31AM
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash Mar 4, 2021 08:30AM
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Mar 4, 2021 08:30AM
View Older Stories

Nov 10, 2020 07:00PM Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-
Nov 10, 2020 07:00PM Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-
Apr 22, 2020 04:05PM Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
Mar 13, 2020 09:26AM Five Prime Therapeutics (FPRX) Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
Mar 13, 2020 09:25AM Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
Feb 27, 2020 04:05PM Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
Feb 13, 2020 04:05PM Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call
Oct 24, 2019 04:01PM Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call
Oct 10, 2019 04:02PM Five Prime Therapeutics (FPRX) to Restructure, Cutting 70 Jobs
Oct 10, 2019 04:01PM Five Prime Announces Restructuring
Sep 30, 2019 06:30AM Five Prime Therapeutics (FPRX) Highlights Updated Data From the Phase 1a/1b Trial of FPA150
Sep 30, 2019 03:01AM Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress
Sep 19, 2019 04:05PM Five Prime Therapeutics Announces Management Transition
Aug 22, 2019 07:45PM Five Prime Therapeutics to Present at Upcoming Healthcare Conference
Aug 7, 2019 04:05PM Five Prime Therapeutics Reports Second Quarter 2019 Results
Jul 31, 2019 09:16PM Five Prime Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call
Jul 31, 2019 09:15PM Five Prime Therapeutics to Present at Upcoming Healthcare Conference
Jun 24, 2019 04:13PM Five Prime Therapeutics (FPRX) Names Lori Lyons-Williams to Board
Jun 24, 2019 04:05PM Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
Jun 10, 2019 05:56AM Five Prime Therapeutics (FPRX) Reports Departure of Dr. Sheila Gujrathi from Board
Jun 9, 2019 03:05PM Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors
Jun 9, 2019 03:00PM Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences
Jun 3, 2019 05:45AM Five Prime Therapeutics (FPRX) Reports Monotherapy Data from Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at ASCO 2019 Meetings
Jun 1, 2019 09:01AM Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting
May 24, 2019 04:01PM Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences
May 16, 2019 10:58AM Five Prime Therapeutics (FPRX) Names Carol Schafer to Board
May 15, 2019 06:39PM Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors
May 15, 2019 05:45PM Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting
May 8, 2019 04:05PM Five Prime Therapeutics Reports First Quarter 2019 Results
Apr 17, 2019 07:56PM Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8
Mar 5, 2019 06:05PM Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
Feb 26, 2019 04:05PM Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 21, 2019 05:51AM Five Prime Therapeutics (FPRX) Reports First Patient Dosing in Phase 1b Trial of FPA150
Feb 20, 2019 08:05PM Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150
Feb 7, 2019 04:05PM Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
Feb 4, 2019 05:05PM Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum
Jan 17, 2019 02:08PM Five Prime Therapeutics (FPRX) Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at ASCO GI Cancers Symposium
Jan 17, 2019 02:05PM Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Jan 15, 2019 04:09PM UPDATE: Five Prime Therapeutics (FPRX) Announces Corporate Restructuring; Will Reduce Workforce by Approx. 20%, Projects $2M for Pre-Tax Restructuring Charges During 1Q19
Jan 15, 2019 04:05PM Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities
Jan 14, 2019 06:41PM Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium
Dec 12, 2018 04:05PM Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 29, 2018 04:25PM Five Prime Therapeutics (FPRX) Appoints William Ringo as New Board Chairman Replacing Lewis T. 'Rusty' Williams, MD, PhD.; Mark McDade to Retire from Board
Nov 29, 2018 04:05PM Five Prime Therapeutics Announces Changes to its Board of Directors
Nov 20, 2018 04:05PM Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
Nov 14, 2018 04:31PM Five Prime Therapeutics (FPRX) Commences Patient Dosing in Phase 1 Clinical Trial of FPT155
Nov 14, 2018 04:05PM Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein
Nov 6, 2018 04:05PM Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
Nov 5, 2018 10:36AM Five Prime Therapeutics (FPRX) Says David V. Smith Will Join Company as CFO
Nov 5, 2018 10:36AM Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer
View Older Stories